http://www.law360.com/ Latest articles for organization: Forest Laboratories Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/133217 Forest Laboratories Inc. and the U.S. Department of Justice have struck a deal to settle civil claims stemming from investigations into the marketing of antidepressants Celexa and Lexapro and a hypothyroidism treatment, but the pact does not cover an ongoing probe into possible criminal violations related to the drugs. http://www.law360.com/articles/133217 http://www.law360.com/articles/132727 Infosint SA has asked a judge to increase a $15 million reasonable royalty award that a jury issued for Lundbeck A/S and Forest Laboratories Inc.'s alleged infringement of a patent for making the antidepressant citalopram, arguing that it should receive additional damages and interest totaling almost $43 million. http://www.law360.com/articles/132727 http://www.law360.com/articles/128894 Lundbeck A/S and Forest Laboratories Inc. will have to pay Infosint SA a $15 million reasonable royalty award now that a federal jury has ruled that Infosint's patent for making the antidepressant citalopram is valid. http://www.law360.com/articles/128894 http://www.law360.com/articles/128750 Sun India Pharmaceuticals Inc. has backed off from marketing generic tablets of the lucrative Alzheimer's drug Namenda, becoming the latest manufacturer to surrender to Forest Laboratories Inc. in an ongoing patent battle. http://www.law360.com/articles/128750 http://www.law360.com/articles/125335 Forest Laboratories Inc. has moved to settle a lawsuit brought by the U.S. Department of Justice and two whistleblowers accusing the company of bribing doctors to prescribe antidepressants Celexa and Lexapro and marketing the drugs for pediatric use without approval from the U.S. Food and Drug Administration. http://www.law360.com/articles/125335 http://www.law360.com/articles/121851 A judge has signed off on a request to dismiss Upsher-Smith Laboratories Inc., Wockhardt Ltd., Amneal Pharmaceuticals LLC and Apotex Corp. from a patent suit that Forest Laboratories brought to protect the lucrative market for the Alzheimer's drug Namenda from generic competition. http://www.law360.com/articles/121851 http://www.law360.com/articles/111075 An Alabama judge reportedly declared a mistrial on Monday in a trial for a lawsuit filed by the Alabama attorney general against Watson Pharmaceuticals Inc., accused of taking part in an industrywide scheme to bilk Medicaid by inflating drug prices. http://www.law360.com/articles/111075 http://www.law360.com/articles/110772 Sun Pharmaceutical Industries Ltd. has reached a deal with Forest Laboratories Inc. to license several patents related to the antidepressant Lexapro, bringing an end to a long-running patent suit between the drugmakers. http://www.law360.com/articles/110772 http://www.law360.com/articles/109269 A federal judge has rejected the latest bid from H. Lundbeck A/S and its partner Forest Laboratories Inc. to pare down a patent dispute related to the antidepressant citalopram, ruling that a lone letter from one of the companies' suppliers did not yield enough evidence to drop part of Infosint SA's infringement claims. http://www.law360.com/articles/109269 http://www.law360.com/articles/108907 A federal appeals court has agreed to a further suspension in the appeal of a shareholder derivative suit alleging that certain Forest Laboratories Inc. executives misled shareholders about the company's main products, blockbuster antidepressant drugs Celexa and Lexapro, because the two sides are currently discussing “partial resolution” of the case. http://www.law360.com/articles/108907 http://www.law360.com/articles/104019 In a blow to both sides battling over conflicting patents related to the antidepressant citalopram, a federal judge has found two claims of plaintiff Infosint SA's patent obvious but also invalidated the first claim of defendant H. Lundbeck A/S' patent after finding the company had suppressed or concealed its invention. http://www.law360.com/articles/104019 http://www.law360.com/articles/103802 A federal judge has shot down a bid to consolidate a newly filed proposed class action with multidistrict litigation over Lexapro and Celexa, saying the new product liability lawsuit asserts allegations relating to Forest Laboratories Inc.'s marketing of the drugs, while the MDL relates only to damages for personal injuries arising from suicidality. http://www.law360.com/articles/103802 http://www.law360.com/articles/103058 The state of Alabama has struck an $89 million deal with six major drugmakers accused of overcharging the Alabama Medicaid Agency, including Sanofi-Aventis and Abbott Laboratories, in ongoing litigation alleging dozens of pharmaceutical companies artificially inflated their prices. http://www.law360.com/articles/103058 http://www.law360.com/articles/100317 In a patent infringement suit brought by Infosint SA over the antidepressant citalopram, a federal judge has refused to limit Forest Laboratories Inc.'s liability through a law meant to protect "innocent infringers" before they know about a patent. http://www.law360.com/articles/100317 http://www.law360.com/articles/96920 A federal district judge has granted a spoliation hearing to determine whether Forest Laboratories Inc. improperly destroyed key documents related to its infringement suit against Caraco Pharmaceutical Laboratories Ltd. over a patent for the depression treatment Lexapro. http://www.law360.com/articles/96920 http://www.law360.com/articles/96001 Thursday is the deadline for 14 drugmakers — including Pfizer Inc., Eli Lilly & Co. and GlaxoSmithKline PLC — to respond to the U.S. Food and Drug Administration's complaint that they are violating the law by omitting risk information in sponsored links on Google and other search engines. http://www.law360.com/articles/96001 http://www.law360.com/articles/95521 Officials at the U.S. Food and Drug Administration have expressed concern about a risk of cardiac arrhythmia and death associated with Danish drugmaker H. Lundbeck A/S's proposed schizophrenia drug Serdolect. http://www.law360.com/articles/95521 http://www.law360.com/articles/86436 Since KSR, the Federal Circuit has made three decisions relating to the obviousness of enantiomers over prior art racemates. These decisions suggest that in appropriate cases the court will still place considerable weight on the unpredictability of pharmaceutical research and decline to find such patents obvious, say Monica Bhattacharyya and David Galluzzo of Kasowitz Benson Torres and Friedman LLP. http://www.law360.com/articles/86436 http://www.law360.com/articles/91761 Pfizer Inc., Forest Laboratories Inc. and Warner-Lambert Co. have been hit with a proposed class action accusing them of coordinating a scheme to mask suicide risks associated with antidepressants Lexapro and Celexa in pediatric patients while simultaneously offering doctors kickbacks to prescribe the drugs for younger patients. http://www.law360.com/articles/91761 http://www.law360.com/articles/88957 Federal authorities have unsealed a complaint accusing Forest Laboratories Inc. of bribing doctors to prescribe the antidepressants Celexa and Lexapro and marketing the drugs for pediatric use without approval. http://www.law360.com/articles/88957